Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations

The routine use of recombinant erythropoiesis-stimulating agents (ESA) over the past three decades has enabled the partial correction of anaemia in most patients with end-stage renal disease (ESRD). Since ESA use frequently leads to iron deficiency, almost all ESA-treated haemodialysis patients worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rostoker, Guy, Vaziri, Nosratola D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627982/
https://www.ncbi.nlm.nih.gov/pubmed/31338466
http://dx.doi.org/10.1016/j.heliyon.2019.e02045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627982/
https://www.ncbi.nlm.nih.gov/pubmed/31338466
http://dx.doi.org/10.1016/j.heliyon.2019.e02045

Ejemplares similares